Selected Grants
STARS Extension Study
Clinical TrialPrincipal Investigator · Awarded by VectivBio AG · 2022 - 2032Mitigating Ischemia-Reperfusion Injury to Intestinal Allografts Using Normothermic Machine Perfusion
ResearchPrincipal Investigator · Awarded by North Carolina State University · 2024 - 2028OCS Liver Perfusion (OLP-II) Registry Pro00113873
Clinical TrialPrincipal Investigator · Awarded by TransMedics · 2023 - 2028OrganOx metra® New Enrollment Post-Approval Study Protocol
Clinical TrialPrincipal Investigator · Awarded by OrganOx Ltd · 2023 - 2028Paragonix LIVERguard
Clinical TrialPrincipal Investigator · Awarded by Paragonix · 2022 - 2027STARS Extension Study
Clinical TrialPrincipal Investigator · Awarded by VectivBio AG · 2022 - 2032Mitigating Ischemia-Reperfusion Injury to Intestinal Allografts Using Normothermic Machine Perfusion
ResearchPrincipal Investigator · Awarded by North Carolina State University · 2024 - 2028OCS Liver Perfusion (OLP-II) Registry Pro00113873
Clinical TrialPrincipal Investigator · Awarded by TransMedics · 2023 - 2028OrganOx metra® New Enrollment Post-Approval Study Protocol
Clinical TrialPrincipal Investigator · Awarded by OrganOx Ltd · 2023 - 2028Paragonix LIVERguard
Clinical TrialPrincipal Investigator · Awarded by Paragonix · 2022 - 2027Molecular Assessment and Profiling of Liver transplant rEcipients: The MAPLE Study - Pro00108291
Clinical TrialPrincipal Investigator · Awarded by CareDx, Inc. · 2021 - 2026A multicenter, double-blind, randomized, placebo-controlled trial to evaluate the efficacy and safety of apraglutide in adult subjects with short bowel syndrome and intestinal failure (SBS-IF)
Clinical TrialPrincipal Investigator · Awarded by VectivBio AG · 2021 - 2026FP-Assessment of Biomarker Guided CNI Substitution in Kidney Transplantation
Clinical TrialPrincipal Investigator · Awarded by Cedars Sinai Medical Center · 2023 - 2025Assessment of Biomarker Guided CNI Substitution in Kidney Transplantation
Clinical TrialPrincipal Investigator · Awarded by Cedars Sinai Medical Center · 2023 - 2025NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements
ResearchInvestigator · Awarded by Washington University in St. Louis · 2024 - 2025International Intestinal Failure Registry - Pro00100987
ResearchPrincipal Investigator · Awarded by The Transplantation Society · 2021 - 2024Impact of Visual Education on Adolescent Liver Transplant Patients' Transition Readiness
ResearchPrincipal Investigator · Awarded by American Society of Transplant Surgeons · 2022 - 2024Health System Outreach to Eliminate Disparities in Living Kidney Transplants
ResearchCo Investigator · Awarded by Wake Forest University Health Sciences · 2023 - 2024Effects of storage method on intestinal allograft immune profile and viability
ResearchPrincipal Investigator · Awarded by Department of Defense · 2019 - 2024Clinical use of Teduglutide in children with short bowel syndrome: a multi-center post-marketing evaluation
Clinical TrialPrincipal Investigator · Awarded by Boston Children's Hospital · 2021 - 2024Protara- THRIVE Study - Pro00108876
Clinical TrialPrincipal Investigator · Awarded by Protara Therapeutics, Inc · 2021 - 2024Novartis - CCFZ533A2202 - Liver Transplant Patients
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2019 - 2024Sample Collection for Prospera Enhancement by Detecting dd-cfDNA Levels (PEDAL Study)
Clinical TrialPrincipal Investigator · Awarded by Natera, Inc · 2021 - 2024Short Bowel Syndrome Registry
ResearchPrincipal Investigator · Awarded by Shire Pharmaceutical Development US Inc. · 2017 - 2023A multicenter randomized, controlled trial to compare the efficacy of ex-vivo normothermic machine perfusion with static cold storage in human liver transplantation
Clinical TrialPrincipal Investigator · Awarded by OrganOx Ltd · 2016 - 2023Helping Patients Achieve Kidney Transplants through Health System Change
ResearchInvestigator · Awarded by Patient-Centered Outcomes Research Institute · 2022 - 2023Health system outreach to eliminate disparities in living kidney transplants
ResearchCo Investigator · Awarded by National Institutes of Health · 2020 - 2023Novartis - CFZ533A2201 Study for Kidney Transplant Patients
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2018 - 2023A Phase 2a Randomized open label study to assess Bleselumab
Clinical TrialPrincipal Investigator · Awarded by Astellas Pharma Global Development, Inc · 2017 - 2022Transplant Genomics - TruGraf testing
Clinical TrialPrincipal Investigator · Awarded by Transplant Genomics Inc. · 2019 - 2021A Prospective, Open-Label, Long-Term Safety and Efficacy of Teduglutide
Clinical TrialPrincipal Investigator · Awarded by Shire Human Genetics Therapies · 2016 - 2021BMS-EnList
Clinical TrialPrincipal Investigator · Awarded by The Bristol-Myers/Sanofi Pharmaceuticals, Inc. Partnership · 2016 - 2020A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF QPI-1002 FOR PREVENTION OF DELAYED GRAFT FUNCTION IN RECIPIENTS OF A DONATION AFTER BRAIN DEATH OLDER DONOR KIDNEY TRANSPLANT (ReGIFT)
Clinical TrialPrincipal Investigator · Awarded by Quark Pharmaceuticals, Inc · 2016 - 2020Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Through 17
Clinical TrialPrincipal Investigator · Awarded by NPS Pharmaceuticals · 2016 - 2019Evaluation of Acute Rejection Rates in de novo Renal Transplant Recipients Following Thymoglobulin Induction, CNI-free, Nulojix (belatacept) -based Immunosuppression
Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2014 - 2017A randomized, parallel-group, double-blind, placebo-controlled, multi-center study of eculizumab for the prevention of delayed graft function after kidney transplantation in adult subjects at increased risk of delayed graft function
Clinical TrialPrincipal Investigator · Awarded by Alexion Pharmaceuticals, Inc. · 2014 - 2016External Relationships
- Singapore General Hospital
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.